Adalimumab – a new TNF-α antibody for treatment of inflammatory joint disease
Authors:
- Klaus P MacholdKMKlaus P Machold
- Josef S SmolenJSJosef S Smolen
- 1 April 2003
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 3 (2) , 351-360
Abstract
Tumour necrosis factor alpha (TNF-alpha) is a pro-inflammatory cytokine with various roles in inflammatory processes. Several TNF blockers are currently approved for use in rheumatoid arthritis (RA) as well as in other inflammatory arthropathies. The latest of these compounds is the human monoclonal antibody, adalimumab, which was obtained using phage display technology and successfully produced in a mammalian expression system. Clinical application of this compound led to significant improvement in patients suffering from RA, both as monotherapy and in combination with various disease modifying antirheumatic drugs (DMARDs), including methotrexate (MTX). Moreover, radiographic progression is significantly inhibited and quality of life improved. This article summarises the available information.Keywords
This publication has 33 references indexed in Scilit:
- The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD coursesRheumatology, 2002
- COBRA combination therapy in patients with early rheumatoid arthritis: Long‐term structural benefits of a brief interventionArthritis & Rheumatism, 2002
- Distribution of TNF‐α, TNF‐R55 and TNF‐R75 in the Rheumatoid Synovial Membrane: TNF Receptors are Localized Preferentially in the Lining Layer; TNF‐α is Distributed Mainly in the Vicinity of TNF Receptors in the Deeper LayersScandinavian Journal of Immunology, 1999
- Activation of Human Monocytes by LPS and DHEAJournal of Interferon & Cytokine Research, 1998
- Cytokine profile in chronic cardiac failure European Journal of Clinical Investigation, 1996
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functionsCytokine, 1995
- TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?Rheumatology, 1992
- Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritisArthritis & Rheumatism, 1990
- Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serumArthritis & Rheumatism, 1988